Ana Rita Gameiro Costa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ana Rita Gameiro Costa has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Aisha Ahmed
Queen Square MND Centre, UCL Queen Square Institute of Neurology
1 shared publication- Alastair John Noyce
Centre for Preventive Neurology, Wolfson Institute of Population Health Queen Mary University of London London UK
1 shared publication - Alexandra Zirra
Centre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University of London, United Kingdom
1 shared publication - Alexiane Touzé
UCL Huntington’s Disease Centre, UCL Queen Square Institute of Neurology
1 shared publication - Amanda Heslegrave
UK Dementia Research Institute, University College London, London, UK
1 shared publication - Andrea Malaspina
Department of Neuromuscular Diseases, UCL Queen Square Motor Neuron Disease Center, UCL Queen Square Institute of Neurology, University College London, London, UK
1 shared publication
Latest Publications
- Open Access
Validation of remote collection and quantification of blood Neurofilament light in neurological diseases
Promising blood-based biomarkers of neuropathology have emerged with potential for therapeutic development and disease monitoring. However, these tools will require specialist tertiary services for integration into clinical management. Remote sampling for biomarker assessment could ease the burden of in-person clinical visits for such tests and allow for frequent sampling. Here we evaluated a capillary finger-prick collection for remote quantification of blood neurofilament light (NfL), a common blood-based biomarker evident in various neurological disorders, and other exploratory markers of neuronal injury and neuroinflammation (GFAP, tau). Matched samples from venepuncture and finger-prick were collected and processed into plasma and/or serum to directly compare NfL levels across four different neurological conditions (HD, MS, ALS, PD). Two delayed processing conditions were compared, three- and seven-day delay, simulating ambient shipment. Capillary NfL and GFAP concentrations were equivalent to those in venous blood serum and plasma. Only NfL remained stable after seven-day processing delay. Capillary NfL replicated disease group differences displayed in venous blood. This data supports our finger-prick method for remote collection and quantification of NfL. With the widespread applications for NfL across the spectrum of neurological disorders, this has the potential to transform disease monitoring, prognosis, and therapeutic development within clinical practice and research. Graphical Figure 1
Open AccessValidation of remote collection and quantification of blood Neurofilament light in neurological diseases
Promising blood-based biomarkers of neuropathology have emerged with potential for therapeutic development and disease monitoring. However, these tools will require specialist tertiary services for integration into clinical management. Remote sampling for biomarker assessment could ease the burden of in-person clinical visits for such tests and allow for frequent sampling. Here we evaluated a capillary finger-prick collection for remote quantification of blood neurofilament light (NfL), a common blood-based biomarker evident in various neurological disorders, and other exploratory markers of neuronal injury and neuroinflammation (GFAP, tau). Matched samples from venepuncture and finger-prick were collected and processed into plasma and/or serum to directly compare NfL levels across four different neurological conditions (HD, MS, ALS, PD). Two delayed processing conditions were compared, three- and seven-day delay, simulating ambient shipment. Capillary NfL and GFAP concentrations were equivalent to those in venous blood serum and plasma. Only NfL remained stable after seven-day processing delay. Capillary NfL replicated disease group differences displayed in venous blood. This data supports our finger-prick method for remote collection and quantification of NfL. With the widespread applications for NfL across the spectrum of neurological disorders, this has the potential to transform disease monitoring, prognosis, and therapeutic development within clinical practice and research. Graphical Figure 1